Ca2+Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase
Top Cited Papers
- 1 October 2003
- journal article
- review article
- Published by American Physiological Society in Physiological Reviews
- Vol. 83 (4), 1325-1358
- https://doi.org/10.1152/physrev.00023.2003
Abstract
Somlyo, Andrew P., and Avril V. Somlyo. Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase. Physiol Rev 83: 1325-1358, 2003; 10.1152/physrev.00023.2003.— Ca2+ sensitivity of smooth muscle and nonmuscle myosin II reflects the ratio of activities of myosin light-chain kinase (MLCK) to myosin light-chain phosphatase (MLCP) and is a major, regulated determinant of numerous cellular processes. We conclude that the majority of phenotypes attributed to the monomeric G protein RhoA and mediated by its effector, Rho-kinase (ROK), reflect Ca2+ sensitization: inhibition of myosin II dephosphorylation in the presence of basal (Ca2+ dependent or independent) or increased MLCK activity. We outline the pathway from receptors through trimeric G proteins (Gαq, Gα12, Gα13) to activation, by guanine nucleotide exchange factors (GEFs), from GDP · RhoA · GDI to GTP · RhoA and hence to ROK through a mechanism involving association of GEF, RhoA, and ROK in multimolecular complexes at the lipid cell membrane. Specific domains of GEFs interact with trimeric G proteins, and some GEFs are activated by Tyr kinases whose inhibition can inhibit Rho signaling. Inhibition of MLCP, directly by ROK or by phosphorylation of the phosphatase inhibitor CPI-17, increases phosphorylation of the myosin II regulatory light chain and thus the activity of smooth muscle and nonmuscle actomyosin ATPase and motility. We summarize relevant effects of p21-activated kinase, LIM-kinase, and focal adhesion kinase. Mechanisms of Ca2+ desensitization are outlined with emphasis on the antagonism between cGMP-activated kinase and the RhoA/ROK pathway. We suggest that the RhoA/ROK pathway is constitutively active in a number of organs under physiological conditions; its aberrations play major roles in several disease states, particularly impacting on Ca2+ sensitization of smooth muscle in hypertension and possibly asthma and on cancer neoangiogenesis and cancer progression. It is a potentially important therapeutic target and a subject for translational research.Keywords
This publication has 429 references indexed in Scilit:
- Inflammation and cancerNature, 2002
- Structure of the RGS-like Domain from PDZ-RhoGEF: Linking Heterotrimeric G Protein-Coupled Signaling to Rho GTPasesStructure, 2001
- cGMP-Dependent Protein Kinase Phosphorylates and Inactivates RhoABiochemical and Biophysical Research Communications, 2001
- Phosphorylation of CPI-17, an Inhibitor of Myosin Phosphatase, by Protein Kinase NBiochemical and Biophysical Research Communications, 2000
- Rho-Kinase Inhibitor Retards Migration and in Vivo Dissemination of Human Prostate Cancer CellsBiochemical and Biophysical Research Communications, 2000
- Cyclic GMP-Dependent Stimulation Reverses G-Protein-Coupled Inhibition of Smooth Muscle Myosin Light Chain PhosphataseBiochemical and Biophysical Research Communications, 1996
- Tyrosine Kinase Inhibitors Suppress Agonist-Induced Contraction in Smooth MuscleBiochemical and Biophysical Research Communications, 1993
- Desensitization and muscarinic re-sensitization of force and myosin light chain phosphorylation to cytoplasmic Ca2+ in smooth muscleBiochemical and Biophysical Research Communications, 1990
- Direct regulation of smooth muscle contractile elements by second messengersBiochemical and Biophysical Research Communications, 1989
- The action of various cations on muscle protoplasmJournal of Cellular and Comparative Physiology, 1947